Merck and Moderna announced positive Phase 3 results for intismeran autogene (mRNA-4157/V940) in high-risk melanoma, marking the first successful late-stage trial for an individualized neoantigen therapy.Chemical & Engineering NewspharmaphorumNBC News
The personalized mRNA vaccine, combined with Keytruda, met primary endpoints for recurrence-free and distant metastasis-free survival in a 1,137-patient study.FOX 5 New YorkSOFXNBC NewsABC7 Bay Area
Moderna and Merck’s personalized mRNA vaccine met its main goal in a late-stage melanoma trial when combined with Keytruda. The treatment significantly reduced the risk of high-risk skin cancer returning compared to standard therapy, validating the neoantigen approach in a pivotal setting.
The Phase 3 trial of intismeran autogene involved 1,137 patients with high-risk melanoma whose tumors had been surgically removed. Patients receiving the vaccine plus Keytruda met the primary goal of reducing cancer return and spread compared to Keytruda alone, though detailed statistical data has not yet been released.
Success in this large melanoma trial raises hopes that personalized neoantigen vaccines could be applied to other cancer types. Unlike broad immunotherapies, the vaccine is custom-built for each patient by instructing the immune system to attack mutations unique to their specific tumor.
STAT’s Adam Feuerstein characterizes 2026 as one of the most consequential years in cancer treatment, citing this mRNA neoantigen success alongside Revolution Medicines’ KRAS drug. The positive late-stage readout signals a major shift in the therapeutic landscape for solid tumors.
Personalized cancer vaccine shows positive late-stage trial results, reinforcing the strategic value of mRNA-based immunotherapies. The success in melanoma provides a proof-of-concept for broader application across other tumor types.
Merck and Moderna’s success opens a new avenue of treatment that doctors hope will work against many types of tumors. Unlike chemotherapy, the personalized vaccine trains the immune system to specifically target mutations found only on a person's tumor, with thousands of melanoma patients expected to benefit upon approval.
This marks the first positive Phase 3 data for an individualized neoantigen therapy or mRNA-based cancer vaccine. Intismeran delivers mRNA encoding tumor-specific mutations identified from a patient's removed tumor, bundled in lipid nanoparticles to train the immune system against recurrence.
MSD and Moderna reported positive Phase 3 results for intismeran autogene in combination with Keytruda, meeting primary endpoints for recurrence-free survival (RFS) and distant metastasis-free survival (DMFS). The INTerpath-001 trial represents a historic win for the individualized neoantigen therapy class.
Moderna CEO Stéphane Bancel described the success of intismeran autogene as turning an aspirational vision into reality. The customized treatment uses patient tumor tissue to train the immune system, targeting high-risk melanoma stages that were surgically removed but carried a high chance of recurrence.
This week’s BioPharm Brief covers positive phase 3 melanoma results for Merck and Moderna’s individualized neoantigen therapy, a personalized cancer vaccine manufacturing platform entering clinical use, and a new brain-penetrant antibody approach for glioblastoma. Welcome to The …
Merck and Moderna announced that the vaccine-drug combo extended the time before cancer returned in high-risk patients, though specific duration metrics were not disclosed. Interim data from an earlier ASCO presentation indicated a halving of melanoma return risk after five years.
The regimen is the first and only combination to demonstrate success in potentially extending melanoma lifespans in Phase 3. Previous Phase 2b data showed a 49% reduction in return and 59% reduction in metastasis, with regulatory review pending full data submission to the FDA.
Moderna’s personalized cancer vaccine has scored a late-stage win, validating the commercial and clinical viability of neoantigen targeting. This success establishes a new standard for adjuvant treatment in high-risk melanoma patients.